Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of combination of ergosterol and gefitinib

A technology of ergosterol and gefitinib, which is applied in the field of biomedicine, can solve problems such as multidrug resistance, and achieve the effect of increasing sensitivity

Active Publication Date: 2020-03-17
ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the clinical first-line chemotherapy drugs (platinum, doxorubicin, paclitaxel, etc.) will have multidrug resistance during chemotherapy, which will eventually lead to further progression of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of ergosterol and gefitinib
  • Application of combination of ergosterol and gefitinib
  • Application of combination of ergosterol and gefitinib

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0037] The present invention will be further explained below in conjunction with the accompanying drawings.

[0038] Mechanism of ergosterol combined with gefitinib to induce apoptosis of non-small cell lung cancer cells in vitro

[0039] 1. Experimental materials

[0040] Human lung cancer cell A549 was obtained from the cell bank of the Institute of Life Sciences, Chinese Academy of Sciences, and human lung cancer cell PC-9 was obtained from Shanghai Mingjin Biotechnology Co., Ltd.

[0041] 2. Methods and Results

[0042] (1) Cell culture

[0043] Put the cells into a cell culture flask, add 5-6 ml of complete medium containing 10% fetal bovine serum (FBS), blow evenly and place at 37°C, 5 % CO 2 In the incubator, observe the cell growth status every day, replace the medium every 2-3 days, and pass the cells or cryopreservation when the cells are full to about 80% of the bottom area of ​​the culture flask.

[0044] (2) Cell passage

[0045] Passage when the cells are 80...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention, which belongs to the technical field of biological medicine, relates to drug combination for treating non-small cell lung cancer, in particular to application of combination of ergosterol and gefitinib. Lung cancer A549 cells and PC-9 cells are cultured in vitro to research the inhibition effect of the medicine on tumors. With two system cell lines (respectively PC-9 cells sensitiveto GEF and drug-resistant A549 cells), an MTT testing is performed; a Hochest 33258 cell apoptosis test is performed; cell apoptosis and cell cycle are detected by using flow cytometry; and the influence of the EGFR signal path of the cell is examined by a Western-blots test. Whether ERG and GEF combined application has a synergistic lung cancer resisting effect or not, whether the synergistic and sensitizing effects can be realized for sensitive cell strains or not and whether the sensitivity of drug-resistant cell strains can be improved or not are preliminarily discussed; and the treatmenteffect and mechanism research on non-small cell lung cancer are also discussed.

Description

technical field [0001] The invention relates to a combined drug for treating non-small cell lung cancer, in particular to the use of ergosterol combined with gefitinib. It belongs to the field of biomedical technology. Background technique [0002] Cancer remains one of the world's greatest concerns due to the continued increase in morbidity and mortality. According to statistics, in 2015, there were about 4.3 million new cancer cases and about 2.81 million cancer deaths in China, among which lung cancer took the first place. The Global Cancer Incidence and Mortality Estimates 2018, produced by the International Agency for Research on Cancer, provides a status report on the global cancer burden, with an estimated 18.1 million new cancer cases and 9.6 million cancers in 2018 death cases. Lung cancer was the most common cancer (11.6% of total cases) and the leading cause of cancer death (18.4% of total cancer deaths). It is clinically found that lung adenocarcinoma has gra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/575A61P35/00A61K31/5377
CPCA61K31/575A61K31/5377A61P35/00A61K2300/00
Inventor 黄绳武黄挺吴梅佳
Owner ZHEJIANG CHINESE MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com